Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Glass, Carolyn ^a   Wuertzer, Charles ^a   Cui, Xiaohui ^a   Bi, Yingtao ^b   Davuluri, Ramana ^b   Xiao, Ying Yi ^c   Wilson, Michael ^a   Owens, Kristina ^a   Zhang, Yi ^a   Perkins, Archibald ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b WISTAR INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; PURINERGIC P2X RECEPTOR; RNA; STAT PROTEIN; TRANSCRIPTOME; CCAAT ENHANCER BINDING PROTEIN; CEBPE PROTEIN, HUMAN; DNA BINDING PROTEIN; MECOM PROTEIN, HUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 2; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CEBPE GENE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL DISRUPTION; DOWN REGULATION; DOWNSTREAM PROCESSING; EVI1 GENE; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PROTEIN BINDING; REGULATOR GENE; RNA SEQUENCE; SERPINB2 GENE; SIGNAL TRANSDUCTION; TUMOR GENE; ACUTE MYELOID LEUKEMIA; ANIMAL; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROTO ONCOGENE;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASES; LEUKEMIA, MYELOID, ACUTE; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTO-ONCOGENES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84879532409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067134     Document Type: Article

References (108)

1. Koos Br, Bender S, Witt H, Mertsch S, Felsberg Jr, et al. (2011) The Transcription Factor Evi-1 Is Overexpressed, Promotes Proliferation, and Is Prognostically Unfavorable in Infratentorial Ependymomas. Clinical Cancer Research 17: 3631-3637.
2. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A, (2010) Evaluation of EVI1 and EVI1s (Δ324) as potential therapeutic targets in ovarian cancer. Gynecologic Oncology 118: 189-195.
3. Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters STJCM, van Wering ER, et al. (2010) EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia\ 24\: 942\-949\.
4. Bindels EMJ, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, et al. (2012) EVI1 is critical for the pathogenesis of a subset of MLL-AF9'Äìrearranged AMLs. Blood 119: 5838-5849.
5. Fears S, Mathieu C, Zeleznick-Le N, Huang S, Rowley J, et al. (1996) Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 93: 1642-1647.
6. Buonamici S, Chakraborty S, Senyuk V, Nucifora G, (2003) The role of EVI1 in normal and leukemic cells. Blood cells, Molecules, and Diseases 31: 206-212.
7. Lugthart S, Groschel S, Beverloo H, Kayser S, Valk P, et al. (2010) Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia. J Clin Oncol 28: 3890-3898.
8. De Braekeleer E, Douet-Guilbert N, Basinko A, Bovo C, Gueganic N, et al. (2011) Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26). Anticancer Research 31: 3441-3448.
9. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, et al. (2011) Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117: 6304-6314.
10. Buonamici S, D L, Chi Y, Zhao R, Wang X, et al. (2004) EVI1 induces myelodysplastic syndrome in mice. J Clin Invest 114: 713-719.
11. Cuenco G, Ren R, (2004) Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene 23: 569-579.
12. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, et al. (2011) Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117: 3617-3628.
13. Jin G, Yamazaki Y, Takuwa M, Takahara T, Kaneko K, et al. (2007) Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood 109: 3998-4005.
14. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, et al. (1988) Retroviral activation of a novel gene encoding a zinc finger protein in IL3-dependent myeloid leukemia cell lines. Cell 54: 831-840.
15. Bartholomew C, Clark AM, (1994) Induction of two alternatively spliced evi-1 proto-oncogene transcripts by cAMP in kidney cells. Oncogene 9: 939-942.
16. Bordereaux D, Fichelson S, Tambourin P, Gisselbrecht S, (1990) Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ by the number of zinc finger motifs. Oncogene 5: 925-927.
17. Morishita K, Parganas E, Douglass EC, Ihle JN, (1990) Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: Sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene 5: 963-971.
18. Funabiki T, Kreider BL, Ihle JN, (1994) The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence GAAGATGAG. Oncogene 9: 1575-1581.
19. Perkins AS, Fishel R, Jenkins NA, Copeland NG, (1991) Evi-1, a murine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding protein. Mol Cell Biol 11: 2665-2674.
20. Zhang Y, Sicot G, Cui X, Vogel M, Wuertzer C, et al. (2011) Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide. Biochemistry 50: 10431-10441.
21. Bartholomew C, Kilbey A, Clark A, Walker M, (1997) The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene 14: 569-577.
22. Kim J, Hui P, Yue D, Aycock J, Leclerc C, et al. (1998) Identification of candidate target genes for EVI1, a zinc finger oncoprotein, using a novel selection strategy. Oncogene 17: 1527-1538.
23. Yatsula B, Lin S, Read A, Poholek A, Yates K, et al. (2005) Identification of binding sites of EVI1 in mammalian cells. J Biol Chem 280: 30712-30722.
24. Qiu Y, Lynch J, Guo L, Yatsula B, Perkins A, et al. (2008) Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factors. Biochemistry 47: 3697-3704.
25. Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, et al. (2009) Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene\ 28\: 4364\-4374\.
26. De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, et al. (2011) EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. British Journal of Haematology 154: 337-348.
27. Pradhan AK, Kuila N, Singh S, Chakraborty S, (2011) EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1. Biochimica et Biophysica Acta (BBA)- Gene Regulatory Mechanisms 1809: 269-275.
28. Bard-Chapeau EA, Jeyakani J, Kok CH, Muller J, Chua BQ, et al. (2012) Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proceedings of the National Academy of Sciences 109: 2168-2173.
29. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez M, et al. (2012) Overexpression of SET is a recurrent event associated with poor outcome and\ contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 97: 543-550.
30. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, et al. (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. Embo J 24: 1976-1987.
31. Shimamoto T, Ohyashiki J, Ohyashiki K, Kawakubo K, Kimura N, et al. (1994) GATA-1, GATA-2, and stem cell leukemia gene expression in acute myeloid leukemia. Leukemia 8: 1176-1180.
32. Shaulian E, Karin M, (2001) AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400.
33. Kreider B, Orkin S, Ihle J, (1993) Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid transforming gene. Proc Natl Acad Sci, USA 90: 6454-6458.
34. Morishita K, Parganas E, Matsugi T, Ihle JN, (1992) Expression of the Evi-1 zinc finger gene in 32Dcl3 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol 12: 183-189.
35. Khanna-Gupta A, Lopingco M, Savinelli T, Zibello T, Berliner N, et al. (1996) Retroviral insertional activation of the Evi1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line, 32DCl3. Oncogene 12: 563-569.
36. Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G, (2009) EVI1 Impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 69: 1633-1642.
37. Zhang Y, Stehling-Sun S, Lezon-Geyda K, Juneja S, Coillard L, et al. (2011) PR domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cells function. Blood 118: 3853-3861.
38. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, et al. (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3: 207-220.
39. Valk P, Verhaak R, Beijen M, Erpelinck C, Doorn-Khosrovani S, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. New Engl J Med 350: 1617-1628.
40. Pradhan AK, Mohapatra AD, Nayak KB, Chakraborty S, (2011) Acetylation of the proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS One 6: e25370.
41. Liu Y, Chen L, Ko T, Fields A, Thompson E, (2006) Evi1 is a survival factor which conveys resistance to both TGFb- and taxol-mediated cell death via PI3K/AKT. Oncogene advance online publication 25: 3565-3575.
42. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, et al. (2000) The Evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 19: 2958-2968.
43. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, et al. (2001) The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 97: 2815-2822.
44. Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G, (2001) Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles. J Biol Chem 276: 44936-44943.
45. Kilbey A, Stephens V, Bartholomew C, (1999) Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts. Cell Growth Diff 10: 601-610.
46. Sitailo S, Sood R, Barton K, Nucifora G, (1999) Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Leukemia 13: 1639-1645.
47. Kilbey A, Alzuherri H, McColl J, Cales C, Frampton J, et al. (2005) The Evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity. British Journal of Haematology 130: 902-911.
48. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, et al. (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. Embo J 24: 1976-1987.
49. Jiao X, Sherman B, Huang da, W, Stephens R, et al. (2012) DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics 28: 1805-1806.
50. Durfee LA, Huibregtse JM, (2012) The ISG15 conjugation system. Methods in molecular biology (Clifton, NJ) 832: 141-149.
51. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, et al. (2003) Protein ISGylation modulates the JAK-STAT signaling pathway. Genes & Development 17: 455-460.
52. Zhang X, Meng L, He B, Chen J, Liu P, et al. (2009) The role of P2X7 receptor in ATP-mediated human leukemia cell death: calcium influx-independent. Acta biochimica et biophysica Sinica 41: 362-369.
53. Mane SP, Modise T, Sobral BW, (2011) Analysis of high-throughput sequencing data. Methods in molecular biology (Clifton, NJ) 678: 1-11.
54. Machanick P, Bailey T, (2011) MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics 27: 1696-1697.
55. Bi Y, Kim H, Gupta R, Davuluri RV (2011) Tree-based position weight matrix approach to model transcription factor binding site profiles.
56. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, et al. (2010) GREAT improves functional interpretation of cis-regulatory regions. Nat Biotech 28: 495-501.
57. Hu M, Yu J, Taylor JMG, Chinnaiyan AM, Qin ZS, (2010) On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Research 38: 2154-2167.
58. Yamanaka R, Kim G, Radomska H, Lekstrom-Himes J, Smith L, et al. (1997) CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc Natl Acad Sci USA 94: 6462-6467.
59. Akagi T, Thoennissen N, George A, Crooks G, Song J, et al. (2010) In Vivo Deficiency of Both C/EBPβ and C/EBPε Results in Highly Defective Myeloid Differentiation and Lack of Cytokine Response. PLoS One 5: e15419.
60. Nakajima H, Watanabe N, Shibata F, Kitamura T, Ikeda Y, et al. (2006) N-terminal Region of CCAAT/Enhancer-binding Protein œμ Is Critical for Cell Cycle Arrest, Apoptosis, and Functional Maturation during Myeloid Differentiation. Journal of Biological Chemistry 281: 14494-14502.
61. Halene S, Gaines P, Sun H, Zibello T, Lin S, et al. (2010) C/EBPepsilon directs granulocytic-vs-monocytic lineage determination and confers chemotactic function via Hlx. Experimental Hematology 38: 90-103.e104.
62. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L (2000) Neutrophils: Molecules, Functions and Pathophysiological Aspects. Lab Invest\ 80\: 617\-653\.
63. Khanna-Gupta A, Zibello T, Idone V, Sun H, Lekstrom-Himes J, et al. (2005) Human neutrophil collagenase expression is C/EBP-dependent during myeloid development. Experimental Hematology 33: 42-52.
64. Gombart AF, Kwok SH, Anderson KL, Yamaguchi Y, Torbett BE, et al. (2003) Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBPŒμ and PU.1. Blood 101: 3265-3273.
65. Aaronson DS, Horvath CM, (2002) A road map for those who don't know JAK-STAT. Science (New York, NY) 296: 1653-1655.
66. Hebenstreit D, Horejs-Hoeck J, Duschl A, (2005) JAK/STAT-dependent gene regulation by cytokines. Drug news & perspectives 18: 243-249.
67. Levine R (2011) JAK-Mutant Myeloproliferative Neoplasms. Curr Top Microbiol Immunol.
68. Kiu H, Nicholson SE (2012) Biology and significance of the JAK/STAT signalling pathways. 2 ed. England: Walter & Eliza Hall Institute, 1G Royal Parade, Parkville 3052, Australia. 88-106.
69. Krebs DL, Hilton DJ (2001) SOCS proteins: negative regulators of cytokine signaling. 5 ed. United States: The Walter and Eliza Hall Institute of Medical Research and the Cooperative Research Center for Cellular Growth Factors, Royal Melbourne Hospital, Victoria, Australia. krebs@wehi.edu.au. 378-387.
70. Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F (2001) Constitutive activation of STAT transcription factors in acute myelogenous leukemia. 2 ed. Denmark: Department of Medicine III, Grosshadern, Germany. karsten.spiekermann@med3.med.uni-muenchen.de. 63-71.
71. Yoshimura A, Ichihara M, Kinjyo I, Moriyama M, Copeland NG, et al. (1996) Mouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. 5 ed. ENGLAND: Institute of Life Science, Kurame University, Japan. 1055-1063.
72. Rose TM, Bruce AG, (1991) Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. 19 ed. UNITED STATES: Fred Hutchinson Cancer Research Center, Seattle, WA 98104: 8641-8645.
73. Bruce AG, Linsley PS, Rose TM, (1992) Oncostatin M. 2 ed. ENGLAND: Bristol-Myers Squibb, Pharmaceutical Research Institute-Seattle, WA. 98121: 157-170.
74. Pitha-Rowe IF, Pitha PM (2007) Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. 5-6 ed. England: Dartmouth Medical School, Hanover, NH 03755, United States. 409-417.
75. Andersen JB, Hassel BA (2006) The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe? 6 ed. England: University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA. 411-421.
76. Takeuchi T, Iwahara S, Saeki Y, Sasajima H, Yokosawa H, (2005) Link between the ubiquitin conjugation system and the ISG15 conjugation system: ISG15 conjugation to the UbcH6 ubiquitin E2 enzyme. 6 ed. Japan: Department of Biochemistry, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812: 711-719.
77. Cong X, Yan M, Yin X, Zhang D-E (2010) Hematopoietic cells from Ube1L-deficient mice exhibit an impaired proliferation defect under the stress of bone marrow transplantation. 2 ed. United States: Moores UCSD Cancer Center, University of California San Diego, La Jolla, 92093, USA. 103-111.
78. Genton C, Kruithof E, Schleuning W, (1987) Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol 104: 705-712.
79. Medcalf R, Stasinopoulos S, (2005) The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J 272: 4858-4867.
80. Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, et al. (2003) Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. 18 ed. United States: Australian National Centre for International and Tropical Health and Nutrition, Queensland Institute of Medical Research and University of Queensland, 300 Herston Road, Brisbane, Queensland 4029, Australia. 6520-6532.
81. Yu H, Maurer F, Medcalf R, (2002) Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 99: 2810-2818.
82. Tonnetti L, Netzel-Arnett S, Darnell GA, Hayes T, Buzza MS, et al. (2008) SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. 14 ed. United States: Center for Vascular and Inflammatory Diseases, Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. 5648-5657.
83. Ritchie H, Jamieson A, Booth NA (1995) Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes. 9 ed. UNITED STATES: Department of Molecular and Cell Biology, University of Aberdeen, Scotland, UK. 3428-3435.
84. Gross TJ, Sitrin RG, (1990) The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2. 5 ed. UNITED STATES: Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0360: 1873-1879.
85. Schleuning W, Medcalf R, Hession C, Rothenbuhler R, Shaw A, et al. (1987) Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 7: 4564-4567.
86. Stringer B, Udofa EA, Antalis TM (2012) Regulation of the human plasminogen activator inhibitor type 2 gene: cooperation of an upstream silencer and transactivator. 13 ed. United States: Center for Vascular and Inflammatory Diseases and Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. 10579-10589.
87. Noguchi T, Ishii K, Fukutomi H, Naguro I, Matsuzawa A, et al. (2008) Requirement of reactive oxygen species-dependent activation of ASK1-p38 MAPK pathway for extracellular ATP-induced apoptosis in macrophage. 12 ed. United States: Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, Center of Excellence Program, Japan Science and Technology Corporation, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. 7657-7665.
88. Placido R, Auricchio G, Falzoni S, Battistini L, Colizzi V, et al. (2006) P2X(7) purinergic receptors and extracellular ATP mediate apoptosis of human monocytes/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability. 1 ed. United States: Neuroimmunology Unit, European Centre for Brain Research, S. Lucia Foundation, I.R.C.C.S, Rome, Italy. 10-18.
89. Suh BC, Kim JS, Namgung U, Ha H, Kim KT (2001) P2X7 nucleotide receptor mediation of membrane pore formation and superoxide generation in human promyelocytes and neutrophils. 11 ed. United States: Department of Life Science, Division of Molecular and Life Science, Pohang University of Science and Technology, Hyoja-Dong, Pohang 790-784, Republic of Korea. 6754-6763.
90. North RA (2002) Molecular physiology of P2X receptors. 4 ed. United States: Institute of Molecular Physiology, University of Sheffield, Western Bank, Sheffield, United Kingdom. R.A.North@Sheffield.ac.uk. 1013-1067.
91. Rassendren F, Buell GN, Virginio C, Collo G, North RA, et al. (1997) The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA.9 ed. UNITED STATES: Geneva Biomedical Research Institute, GlaxoWellcome Research and Development, Plan-les-Ouates, 1228 Geneva, Switzerland. FAR14949@ggr.co.uk. 5482-5486.
92. Hewinson J, Moore SF, Glover C, Watts AG, MacKenzie AB (2008) A key role for redox signaling in rapid P2X7 receptor-induced IL-1 beta processing in human monocytes. 12 ed. United States: Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. 8410-8420.
93. Ferrari D, Stroh C, Schulze-Osthoff K (1999) P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. 19 ed. UNITED STATES: Department of Internal Medicine I, Medical Clinics, Eberhard-Karls-University, D-72076 Tubingen, Germany. 13205-13210.
94. Ferrari D, Wesselborg S, Bauer MK, Schulze-Osthoff K (1997) Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. 7 ed. UNITED STATES: Department of Internal Medicine I, Medical Clinics, Eberhard-Karls-University, D-72076 Tubingen, Germany. 1635-1643.
95. Humphreys BD, Rice J, Kertesy SB, Dubyak GR (2000) Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor. 35 ed. UNITED STATES: Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA. 26792-26798.
96. Le Stunff H, Auger R, Kanellopoulos J, Raymond M-N (2004) The Pro-451 to Leu polymorphism within the C-terminal tail of P2X7 receptor impairs cell death but not phospholipase D activation in murine thymocytes. 17 ed. United States: Laboratoire d'activation Cellulaire et Transduction des Signaux, Institut de Biochimie et de Biophysique Moleculaire et Cellulaire, UMR 8619 CNRS, Batiment 430, Universite Paris-Sud, 91405 Orsay Cedex, France. 16918-16926.
97. Gu BJ, Zhang W, Worthington RA, Sluyter R, Dao-Ung P, et al. (2001) A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. 14 ed. United States: Departments of Medicine and Anatomy and Histology, University of Sydney, Sydney, New South Wales 2006: 11135-11142.
98. Sharrocks AD (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol\ 2\: 827\-837\.
99. Shaw PE, Saxton J, (2003) Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases. The International Journal of Biochemistry & Cell Biology 35: 1210-1226.
100. Swiatkowski S, Seifert H-H, Steinhoff C, Prior A, Thievessen I, et al. (2003) Activities of MAP-Kinase Pathways in Normal Uroepithelial Cells and Urothelial Carcinoma Cell Lines. Experimental Cell Research 282: 48-57.
101. Duan R, Xie W, Burghardt RC, Safe S, (2001) Estrogen Receptor-mediated Activation of the Serum Response Element in MCF-7 Cells through MAPK-dependent Phosphorylation of Elk-1. Journal of Biological Chemistry 276: 11590-11598.
102. Chen AG, Yu ZC, Yu XF, Cao WF, Ding F, et al. (2006) Overexpression of Ets-like protein 1 in human esophageal squamous cell carcinoma. World journal of gastroenterology: WJG 12: 7859-7863.
103. Uht RM, Amos S, Martin PM, Riggan AE, Hussaini IM (2006) The protein kinase C-[eta] isoform induces proliferation in glioblastoma cell lines through an ERK//Elk-1 pathway. Oncogene\ 26\: 2885\-2893\.
104. Odrowaz Z, Sharrocks AD, (2012) ELK1 Uses Different DNA Binding Modes to Regulate Functionally Distinct Classes of Target Genes. PLoS Genet 8: e1002694.
105. Ihle J, Rein A, Mural R (1984) Immunologic and virologic mechanisms in retrovirus-induced murine leukemogenesis. In: Klein G, editor. Adv Oncol. NY: Raven. 95-137.
106. Holmes K, Palaszynski E, Frederickson T, Morse H, Ihle J, (1985) Correlation of cell-surface phenotype with the establishment of interleukin 3-dependent cell lines from wild- mouse murine leukemia virus-induced neoplasms. Proc Natl Acad Sci USA 82: 6687-6691.
107. Witt H, O'Geen H, Kim R (2007) Chromatin immunoprecipitation protocol.
108. Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP (2007) GSEA-P: a desktop application for Gene Set Enrichment Analysis. 23 ed. England: Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. 3251-3253.